Clinical trial · Interventional
Brain Imaging Biomarkers in Patients With Brain Metastasis
Imaging Trial of Biomarkers to Guide Individualized Therapy in Patients With Brain Metastasis Receiving Radiotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A biomarker is a measurable indicator of the severity or presence of some disease state. In this study, brain metastases patients who will be receiving radiation treatment, will undergo CT (Computed Tomography) and MRI (Magnetic Resonance Imaging) scans prior to and after radiation treatment to measure these biomarkers. This is a single-center phase II study to validate the predictive abilities of biomarkers, in terms of determining how patients will respond to radiation treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases, Adult | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT and MRI Scans | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- CT and MRI Scans
- description
- Each patient will undergo a 3T MRI scan as well as a dynamic contrast-enhanced CT scan within one week prior to the start of treatment. Patients will also undergo a research 3T MRI scan and research dynamic contrast-enhanced CT scan at the one week post radiotherapy mark. An MRI scan during their 3 month post-treatment follow up visits will take place as per routine standard of care.
- interventionNames
- Diagnostic Test: CT and MRI Scans
Primary outcomes (3)
- measure
- Response Assessment in Neuro-Oncology (RANO) to validate biomarkers
- timeFrame
- Up to 2 years.
- description
- Using RANO to validate imaging predictive biomarkers of response to radiotherapy
- measure
- Response Evaluation Criteria in Solid Tumors (RECIST) criteria to validate biomarkers
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy proven primary malignancy (original biopsy is adequate as long as the brain imaging is consistent with brain metastases) * At least one index lesion with diameter \> 1cm and without imaging evidence of hemorrhage * Patients age \> 18 years of age * Patients planned for RT to brain metastases * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Previous Whole Brain Radiotherapy * Previous radiosurgery to the index lesion * Individuals unable to undergo contrasted MRI for whatever reason
References
Publications (0)
Data not yet available